ストックスクリーナーアプリを入手
161.78
1.91%
3.03
アフターアワーズ：
161.78
前日終値:
$158.75
開ける：
$160.74
24時間の取引高:
432.93K
Relative Volume:
0.64
時価総額：
$8.28B
収益：
$638.50M
当期純損益:
$-183.17M
株価収益率:
-43.79
EPS:
-3.6943
ネットキャッシュフロー:
$-93.89M
1週間 パフォーマンス:
+2.48%
1か月 パフォーマンス:
-1.49%
6か月 パフォーマンス:
+39.45%
1年 パフォーマンス:
+34.41%
1日の値動き範囲:
$160.60
$163.48
1週間の範囲:
$152.28
$163.48
52週間の値動き範囲:
$86.99
$191.50
Axsome Therapeutics Inc Stock (AXSM) Company Profile
名前
Axsome Therapeutics Inc
セクター
電話
(212) 332-3241
住所
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
161.78 | 8.12B | 638.50M | -183.17M | -93.89M | -3.6943 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | 開始されました | B. Riley Securities | Buy |
| 2025-09-03 | 再開されました | Wells Fargo | Overweight |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-06-03 | 開始されました | Oppenheimer | Outperform |
| 2025-04-07 | 開始されました | Jefferies | Buy |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-12-31 | 繰り返されました | Mizuho | Outperform |
| 2024-09-03 | 開始されました | Wells Fargo | Overweight |
| 2024-08-06 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-07-22 | 開始されました | Needham | Buy |
| 2024-04-29 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-06 | 開始されました | UBS | Buy |
| 2024-01-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-08-08 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 開始されました | Piper Sandler | Neutral |
| 2022-11-01 | 開始されました | Loop Capital | Buy |
| 2022-09-07 | 再開されました | Mizuho | Buy |
| 2021-08-10 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 開始されました | Berenberg | Buy |
| 2021-01-08 | 開始されました | Jefferies | Buy |
| 2020-12-16 | 開始されました | Mizuho | Buy |
| 2020-09-29 | 開始されました | BofA Securities | Underperform |
| 2020-09-10 | 開始されました | Morgan Stanley | Overweight |
| 2020-04-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-14 | 開始されました | Cowen | Outperform |
| 2019-12-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-16 | 繰り返されました | Guggenheim | Buy |
| 2019-10-16 | 開始されました | Guggenheim | Buy |
| 2019-09-18 | 開始されました | William Blair | Outperform |
| 2019-05-28 | 開始されました | SunTrust | Buy |
| 2019-05-23 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-04-08 | 開始されました | SVB Leerink | Outperform |
| 2019-03-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-10-03 | 再開されました | Brean Capital | Buy |
| 2015-12-15 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-12-14 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Axsome Therapeutics Inc (AXSM) 最新ニュース
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool
Guggenheim Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome Therapeutics, Inc. $AXSM Position Increased by Assenagon Asset Management S.A. - MarketBeat
Hypersomnia Pipeline Advances with 3+ Companies Developing Innovative Therapies and Expanding Clinical Research | DelveInsight - Barchart
JPMorgan Chase & Co. Has $30.43 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Market Overview: Is Axsome Therapeutics Inc stock trending bullishTrade Exit Report & Fast Gain Swing Trade Alerts - baoquankhu1.vn
AXSM PE Ratio & Valuation, Is AXSM Overvalued - Intellectia AI
Mizuho reiterates Axsome stock Outperform on Auvelity growth By Investing.com - Investing.com Canada
Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Axsome Therapeutics (AXSM) - The Globe and Mail
Axsome Therapeutics’ Q4 numbers beat Wall Street expectations: Analyst sees over 23% upside for stock - MSN
Superstring Capital's New Axsome Therapeutics Position: A $6.84M Biopharma InvestmentNews and Statistics - IndexBox
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain - AOL.com
Wolfe Research initiates coverage of Axsome Therapeutics (AXSM) with outperform recommendation - MSN
Axsome shares slip despite fourth-quarter earnings beat and strong revenue growth - MSN
(AXSM) Risk Channels and Responsive Allocation - Stock Traders Daily
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision - AOL.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Purchased by Eventide Asset Management LLC - MarketBeat
A Look At Axsome Therapeutics (AXSM) Valuation As Legal Probe And FDA Decision Draw Investor Focus - simplywall.st
Profit Review: How much upside does Axsome Therapeutics Inc have2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn
AXSM's 2025 Revenue Growth Primarily Fueled by Auvelity: What Does the Future Hold? - Bitget
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead? - TradingView
RBC Capital reiterates Axsome Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada
Axsome Therapeutics Highlights Auvelity’s $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference - MarketBeat
Is It Time To Revisit Axsome Therapeutics (AXSM) After Recent Share Price Weakness - simplywall.st
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Axsome Therapeutics at The Citizens Life Sciences Conference: Strategic Growth Plans - Investing.com Canada
AXSM: Major 2026 catalysts include Auvelity's PDUFA for Alzheimer's agitation and field force expansion - TradingView
AXSM: April 2026 PDUFA for Auvelity in Alzheimer's agitation is a key near-term catalyst - TradingView
A Look At Axsome Therapeutics (AXSM) Valuation After Priority Review And 2025 Revenue Growth - Yahoo Finance
2 Under-the-Radar Stocks to Buy and Hold - The Globe and Mail
Axsome Therapeutics Highlights Auvelity Sales Push, April 30 PDUFA, and Symbravo Launch Updates - MarketBeat
Inceptionr LLC Invests $1.05 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics at Leerink Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
AXSM: Auvelity accelerates growth and pipeline advances with major expansions and new clinical programs - TradingView
Axsome Therapeutics, Inc. $AXSM is Rhenman & Partners Asset Management AB's 8th Largest Position - MarketBeat
(AXSM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Axsome Therapeutics, Inc. $AXSM Shares Sold by Quantbot Technologies LP - MarketBeat
Axsome Therapeutics touts AUVELITY $155M quarter, doubles salesforce ahead of April FDA decision - MarketBeat
Royce & Associates LP Raises Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Sold by Intech Investment Management LLC - MarketBeat
Assessing Axsome Therapeutics (AXSM) Valuation After Earnings Momentum And New Phase 3 Trial Launch - simplywall.st
AXSM Earnings History & Surprises | EPS & Revenue Results | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
Axsome Therapeutics, Inc. $AXSM Position Boosted by TD Asset Management Inc - MarketBeat
Should Axsome’s Revenue Jump and SUNOSI IP Win Require Action From Axsome Therapeutics (AXSM) Investors? - simplywall.st
AXSM: Robust late-stage pipeline and sales force expansion drive growth across CNS and pain markets - TradingView
AXSM: AUVELITY and pipeline assets drive growth, with key FDA decisions and launches ahead - TradingView
Axsome Therapeutics (AXSM): Analyst Consensus Highlights 35% Potential Upside for This Biotech Innovator - DirectorsTalk Interviews
Axsome Therapeutics Aktie: Wachstumskurs bestätigt - sharewise.com
DNB Asset Management AS Increases Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Bought by JPMorgan Chase & Co. - MarketBeat
Axsome Therapeutics Inc (AXSM) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):